Navigation Links
A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Date:10/25/2007

website: http://www.shire.com

"SAFE HARBOR " STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine) extended release (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire's ability to benefit from its acquisition of New River Pharmaceuticals, Inc.; the successful development of JUVISTA(R) (human TGFBeta3) and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.


'/>"/>
SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
7. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
11. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...RNewswire-USNewswire/ -- Forty-two leading U. S. s...ational forum to consider cutting-edge innovations...nal economy from outbreaks of dangerous zoonotic d... Among those innovations: , , , , ...ble that detects highly contagious and dangerous z...
(Date:11/13/2008)...3 Hologic, Inc.,(Nasdaq:...pplier of premium,diagnostics, medical imaging sys...e healthcare needs of women, today announced the r...cal trial. The Cervista HPV high-risk,test is curr...xpected to be,launched in the European Union (EU) ...
(Date:11/12/2008)...ewswire-USNewswire/ -- A new study being,published... answer the,question, what causes Parkinson,s dise...edical research into,Parkinson,s disease is what c...he first place. Answering this question has been e...dentical types of brain cells that produce,dopamin...
(Date:11/12/2008)...0128 Provides Reversible, High-level Platelet ... -, NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., ... biopharmaceutical company developing innovative,d...scular and inflammatory,diseases, and cancer, toda...060128, the Company,s novel anti-platelet drug tha...
Breaking Medicine Technology:42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4A Window Into Parkinson's Disease 2Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders 2Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders 3Health and Business Groups Launch Ad Campaign About Need for Comprehensive Smoke Free Law in Pennsylvania 992 1Health and Business Groups Launch Ad Campaign About Need for Comprehensive Smoke Free Law in Pennsylvania 992 2Health and Business Groups Launch Ad Campaign About Need for Comprehensive Smoke Free Law in Pennsylvania 992 3Slowed Brain Activity in Frequent Mobile Phone Users 989 1Slowed Brain Activity in Frequent Mobile Phone Users 989 2LOreal Paris Celebrates Ten Years of Hope and Healing 986 1LOreal Paris Celebrates Ten Years of Hope and Healing 986 2LOreal Paris Celebrates Ten Years of Hope and Healing 986 3LOreal Paris Celebrates Ten Years of Hope and Healing 986 4LOreal Paris Celebrates Ten Years of Hope and Healing 986 5The Pittsburgh Life Sciences Greenhouse Adds to Its Investment Portfolio 501 1The Pittsburgh Life Sciences Greenhouse Adds to Its Investment Portfolio 501 2The Pittsburgh Life Sciences Greenhouse Adds to Its Investment Portfolio 501 3The Pittsburgh Life Sciences Greenhouse Adds to Its Investment Portfolio 501 4
... 25, 2007 - ARIAD,Pharmaceuticals, Inc. (NASDAQ: A...rom leading cancer centers will present Phase 2 an...any,s novel mTOR,inhibitor, AP23573, at the annual...ogy (ASCO) in Chicago, Illinois, on Sunday, June,3...single-agent,AP23573 in patients with soft-tissue ...
...wswire-FirstCall/ -- Iomai,Corporation today annou...1 trial of its patch-based needle-free influenza v...nce call and live,webcast will be held at 8:30 a.m...Conference Call Details , To access the live confe...rn Time via phone, please dial 888-396-2356 from t...
Other Medicine Technology:Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 2Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 3Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 4Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2
(Date:11/21/2008)...-USNewswire/ -- The Generic,Pharmaceutical Associ...y from,GPhA President and CEO Kathleen Jaeger reg...ble on "Emerging Health Care Competition and Consu...is conducting this roundtable demonstrates the,gr... access to safe and,affordable biogenerics sooner...
(Date:11/21/2008)...ve against Lennox-Gastaut syndrome , , F...ed Banzel (rufinamide) has been approved as a supp...called Lennox-Gastaut syndrome, the U.S. Food and ...roval was based on results of a four-month clinica...red to patients who took a placebo, those who took...
(Date:11/21/2008)...wire/ -- The University of Texas M. D. Anderson ...ive effort to eradicate breast cancer in Panama th...and Research of the Americas today at an event wit... and Vivian Fernandez de Torrijos, the First Lady ...e initiative are the U.S. Department of State and ...
(Date:11/21/2008)...-- NursingCenter.com, the premier site,for online...ntent, has been,updated to improve the interactiv...wered by Lippincott Williams & Wilkins (LWW), ...ewed continuing education activities and free,acc...ursing journals.,Lippincott Williams & Wilkin...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3
...fat the miss, is Texas A&M University. The univers... line-Whole Harvest Culinary Oils. This change is ...odd eateries on campus. Students eat at campus fa...le dining halls, restaurants and food court specia...
...eadaches, but patients should be warned of the ris...scrasias"), concluded a Cochrane Review team. Furt... conclusion involved intravenous infusions of the ...to deliver. Dipyrone is a non-opioid painkiller t...
... aneurysms can sharply reduce the likelihood of dy...d older, according to a new review of recent studi... in half for men ages 65 to 79 but did not reduce ...r, men who received screening were also twice as l...
...r continues unabated. One more firm has said it is... that animals fed the brands had vomited and also ...ood manufacturer has recalled its products on rece...experiencing kidney problems, the Food and Drug Ad...
Other Medicine News:Health News:Screening for Abdominal Aortic Aneurysms Saves Men's Lives 2Health News:Two More Pet Food Products Recalled in US 2Health News:Two More Pet Food Products Recalled in US 3
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution.
For the quantitative determination of total glucose in serum.
Glucose reagent is used for the quantitative determination of glucose in human serum.
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L). Single vial, dry powder reagent.
Medicine Products: